Out of 336 initial submissions across both Business and NPO Tracks, DiaTheris is the winner of Switzerland's leading early-stage startups >>venture>> competition in the vertical “Health and Nutrition” 2023, obtaining 50,000 CHF prize.
DiaTheris is recognized as the most promising startup in the vertical “Health and Nutrition” by a large panel of world-recognized experts from the pharmaceutical and finance industries. DiaTheris is developing the first-ever therapy for type 1 diabetes that enables glycemic control without the associated risks of hypoglycemia or diabetic ketoacidosis. By simplifying and enhancing the treatment of type 1 diabetes, DiaTheris aims to improve the quality of life for patients and their families.
>>venture>> is a joint initiative of ETH Zürich, McKinsey & Company, Knecht Holding, Innosuisse and EPFL and its Advisory Board for this competition is constituted by scientific and economic world top players.
>>venture>> is the leading competition for up-and-coming entrepreneurs in Switzerland.
Founded by Dr. Thomas Knecht in 1997, the competition empowers young innovators to develop their business ideas into startup companies.